Results 241 to 250 of about 10,674,355 (324)
Letter to the Editor Regarding "The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis". [PDF]
Liao KF, Lai SW.
europepmc +1 more source
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD). Methods PrismRA incorporated 19 gene expression features and four clinical features to assess a patient's likelihood of
Fenglong Xie +3 more
wiley +1 more source
Immune Checkpoint Inhibitor Related Myositis and Associated Triad Overlap Syndrome
Objective Immune checkpoint inhibitor (ICI) myositis is a rare but highly morbid condition, particularly with the ICI myositis triad syndrome of myositis, myocarditis, and myasthenia gravis. We report the clinical characteristics of ICI myositis and all‐cause mortality in these patients.
Selene Rubino +9 more
wiley +1 more source
ErB4 and NdB4 nanostructured powders are produced by mechanochemical synthesis. 5 h mechanical alloying and 4 M HCl acid leaching are used in the production. ErB4 and NdB4 powders exhibit maximum magnetization of 0.4726 emu g−1 accompanied with an antiferromagnetic‐to‐paramagnetic phase transition at about TN = 18 K and 0.132 emu g−1 with a maximum at ...
Burçak Boztemur +5 more
wiley +1 more source
Disproportionality analysis of fondaparinux associated adverse events based on the FDA adverse event reporting system. [PDF]
Kang F +6 more
europepmc +1 more source
Retraction and replacement of: An integrated complete-genome sequencing and systems biology approach to predict antimicrobial resistance genes in the virulent bacterial strains of Moraxella catarrhalis. [PDF]
europepmc +1 more source
Correction: A Response to: Letter to the Editor Regarding "The Risk of Herpes Zoster in Patients with Depressive Disorders: A German Claims Database Analysis". [PDF]
Marijic P +11 more
europepmc +1 more source

